DEC-205 Antibody (MG38): sc-23952

DEC-205 Antibody (MG38) is a mouse monoclonal IgG2b kappa light chain antibody that detects DEC-205 protein of human origin by immunofluorescence (IF) and flow cytometry (FCM). DEC-205, also known as LY75 or lymphocyte antigen 75, is a 1,695-residue multilectin receptor that plays a crucial role in the immune system by mediating the uptake of antigens and their presentation to T cells. DEC-205 is primarily expressed in mature dendritic cells, where DEC-205 facilitates the targeting of membrane receptors to endosomes or lysosomes rich in major histocompatibility complex class II (MHC II) products, thereby enhancing the immune response. The structure of DEC-205 includes an extracellular N-terminal cysteine-rich domain, a fibronectin type II domain, and ten C-type carbohydrate recognition domains, along with a single transmembrane region and a small cytoplasmic C-terminal domain containing a critical tyrosine residue at position 1679. This structural configuration is essential for DEC-205 function, as DEC-205 can elicit either an agonistic or antagonistic effect on interleukin-4 (IL-4) signaling, influencing the maturation of epithelial cells or the proliferation of T cells. The versatility of DEC-205 in modulating immune responses makes DEC-205 a significant target for therapeutic interventions and research applications.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DEC-205 Antibody (MG38) References:

1. DEC-205 as a marker of dendritic cells with regulatory effects on CD8 T cell responses.  |  Kronin, V., et al. 2000. Int Immunol. 12: 731-5. PMID: 10784619
2. DEC-205 expression on migrating dendritic cells in afferent lymph.  |  Gliddon, DR., et al. 2004. Immunology. 111: 262-72. PMID: 15009426
3. DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells.  |  Tel, J., et al. 2011. Eur J Immunol. 41: 1014-23. PMID: 21413003
4. DEC-205 is a cell surface receptor for CpG oligonucleotides.  |  Lahoud, MH., et al. 2012. Proc Natl Acad Sci U S A. 109: 16270-5. PMID: 22988114
5. Targeting M2e to DEC-205 induces an enhanced serum antibody-dependent heterosubtypic protection against influenza A virus infection.  |  Padilla-Quirarte, HO., et al. 2019. Vaccine. 37: 2624-2633. PMID: 30955979
6. Advancing immunomodulation by in vivo antigen delivery to DEC-205 and other cell surface molecules using recombinant chimeric antibodies.  |  Iberg, CA. and Hawiger, D. 2019. Int Immunopharmacol. 73: 575-580. PMID: 31228685
7. DEC-205 receptor-mediated long-circling nanoliposome as an antigen and Eucommia ulmoides polysaccharide delivery system enhances the immune response via facilitating dendritic cells maturation.  |  Feng, H., et al. 2020. Drug Deliv. 27: 1581-1596. PMID: 33169636
8. The cryo-EM structure of the endocytic receptor DEC-205.  |  Gully, BS., et al. 2021. J Biol Chem. 296: 100127. PMID: 33257321
9. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.  |  Bhardwaj, N., et al. 2020. Nat Cancer. 1: 1204-1217. PMID: 35121932
10. Identification of a novel DEC-205 binding peptide to develop dendritic cell-targeting nanovaccine for cancer immunotherapy.  |  Zheng, J., et al. 2024. J Control Release. 373: 568-582. PMID: 39067792

The preferred DEC-205 antibody is DEC-205 Antibody (F-4): sc-515016.